2025 Q3 -tulosraportti
85 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 432 651
Myynti
Määrä
2 429 737
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 125 | - | - | ||
| 689 | - | - | ||
| 16 | - | - | ||
| 228 | - | - | ||
| 449 | - | - |
Ylin
377,65VWAP
Alin
366,45VaihtoMäärä
2 264,2 6 104 675
VWAP
Ylin
377,65Alin
366,45VaihtoMäärä
2 264,2 6 104 675
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 6 480 | 6 480 | 0 | 6 480 |
| DnB Bank ASA | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 5 940 447 | 5 940 447 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 143 331 | 143 331 | 0 | 143 331 |
| DCAR | 2 417 | 2 417 | 0 | 2 417 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 6 480 | 6 480 | 0 | 6 480 |
| DnB Bank ASA | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 5 940 447 | 5 940 447 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 143 331 | 143 331 | 0 | 143 331 |
| DCAR | 2 417 | 2 417 | 0 | 2 417 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·57 min sittenI don't really care if the price rises or falls right now. I'm looking at at least a 5-year perspective : Novo Nordisk is extremely strong, not only here and now, but also in the long run. Several structural and strategic factors indicate that the share price has good conditions for a stable, gradual increase over the next five years. 1. Healthcare megatrends speak Novo's language The incidence of diabetes and obesity is rising globally, driven by demographics, urbanization, and lifestyle. Novo Nordisk is a world leader precisely in these diseases and is positioned where demand is growing fastest. 2. Strong pipeline and continuous innovation Novo has repeatedly shown the ability to improve existing treatments and develop new ones. This provides both longer product life cycles and the opportunity to expand indications, an important driver for long-term growth. 3. Scalable business with high earnings The company has a proven ability to translate growth into solid margins and strong cash flow. This allows for investments, acquisitions, share buybacks, and stable dividends, all supporting the share price. 4. Global reach and strong brand Novo Nordisk is not dependent on one market. Its global presence reduces risk and provides access to growth in both mature and new healthcare markets. 5. Long-term management and clear strategy The company is known for disciplined capital allocation and long-term thinking. This gives investors confidence, and confidence is often an underestimated factor behind stable price increases. Overall, Novo Nordisk is an example of a company where long-term societal trends, strong innovation, and a solid business model are moving in the same direction. This does not make the stock risk-free , but it makes it structurally interesting for many years to come.
·1 t sittenWill we close in the green today? 😁
·31 min sittenThanks for your reply. I started here a few days ago so I didn't quite realize it kept running😏·24 min sittenRead along and separate the wheat from the chaff – then the rest is up to you 😉
·2 t sitten · MuokattuThanks to several for putting the sales figures of Wegovy pills into perspective. However, it is important to understand where the weekly prescription numbers come from, because it is only the tip of the iceberg. They are based on data from IQVIA, which are retail pharmacies in the USA, i.e. CVS, Walgreens, Rite Aid, Costco and Walmart, but this ONLY constitutes a smaller part of the sales and mostly says something about the interest in the pill. The pill is also sold through several large sales channels, including NovoCare online (Novo Nordisk's own online pharmacy), telehealth (Ro, GoodRx, LifeMD, Weight Watchers, Amazon Pharmacy etc.) and insurance (Medicaid/Medicare), but all those prescription numbers are invisible and only appear in the quarterly report. The total weekly prescription number is therefore larger than what is published by IQVIA, probably 1.5 - 4 times larger according to estimates from ChatGPT. Furthermore, it is important to include in one's revenue expectations that the price of Wegovy increases when the introductory period expires and when the dose is increased over time. Hope that Novo continues the good start to the year and that we have finally seen a turning point in the share price for shareholders :)
·1 t sittenAgreed, remember the weather can have an impact (less last week, more current), and with the solid go-to-market strategy regarding the commercial part we have seen, I think the other channels will surprise tremendously. However, I think guidance will be affected by a cautious approach, so we probably won't get the fully positive aspect until the q1-26 figures are on the table, but I think it's set for 🚀 by then. Time will tell, but remember guidance is characterized by budget allocation that is probably signed off by November at the latest. P1 actuals are probably not closed on Wednesday and it's too early to update a DF. Anyhow, it will be exciting on Wednesday!
·3 t sittenConsidering buying now?
·5 t sittenSince the first super prescription numbers for the pill came three weeks ago, there has at the time of writing been 5 kr on the price.
·4 t sitten · Muokattu56.000 prescriptions at 149 USD is approximately 56 million kroner. If we calculate with 26.000 prescriptions per week, that gives 1.3 billion DKK in annual revenue. In 2024, NOVO generated 290,4 billion DKK in revenue. 1,3 billion constitutes approximately ~0.5% of total revenue. 5 kr constitutes ~2% of the share price. Why do you think the price should be higher due to the pill sales figures at the current time?·2 t sittenYou are right if NN in the future only sells 26,000 prescriptions per week, i.e. 1.25 million prescriptions per year, then each prescription must cost 19,000 DKK per month to reach 290 billion in revenue per year. So it will be difficult, no matter how you look at it. However, I think the potential is incredibly large with 1 billion potential customers globally. What we have seen in the first few weeks merely shows that there is very great interest in the USA. Regarding the price, 149 USD is an introductory price for some for the first three months. Others have a completely different price. Furthermore, there will be significant sales from NN's own platforms, where NN controls most of the value chain and bypasses expensive sales channels, which will greatly benefit the bottom line.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
85 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·57 min sittenI don't really care if the price rises or falls right now. I'm looking at at least a 5-year perspective : Novo Nordisk is extremely strong, not only here and now, but also in the long run. Several structural and strategic factors indicate that the share price has good conditions for a stable, gradual increase over the next five years. 1. Healthcare megatrends speak Novo's language The incidence of diabetes and obesity is rising globally, driven by demographics, urbanization, and lifestyle. Novo Nordisk is a world leader precisely in these diseases and is positioned where demand is growing fastest. 2. Strong pipeline and continuous innovation Novo has repeatedly shown the ability to improve existing treatments and develop new ones. This provides both longer product life cycles and the opportunity to expand indications, an important driver for long-term growth. 3. Scalable business with high earnings The company has a proven ability to translate growth into solid margins and strong cash flow. This allows for investments, acquisitions, share buybacks, and stable dividends, all supporting the share price. 4. Global reach and strong brand Novo Nordisk is not dependent on one market. Its global presence reduces risk and provides access to growth in both mature and new healthcare markets. 5. Long-term management and clear strategy The company is known for disciplined capital allocation and long-term thinking. This gives investors confidence, and confidence is often an underestimated factor behind stable price increases. Overall, Novo Nordisk is an example of a company where long-term societal trends, strong innovation, and a solid business model are moving in the same direction. This does not make the stock risk-free , but it makes it structurally interesting for many years to come.
- ·1 t sittenWill we close in the green today? 😁·31 min sittenThanks for your reply. I started here a few days ago so I didn't quite realize it kept running😏·24 min sittenRead along and separate the wheat from the chaff – then the rest is up to you 😉
- ·2 t sitten · MuokattuThanks to several for putting the sales figures of Wegovy pills into perspective. However, it is important to understand where the weekly prescription numbers come from, because it is only the tip of the iceberg. They are based on data from IQVIA, which are retail pharmacies in the USA, i.e. CVS, Walgreens, Rite Aid, Costco and Walmart, but this ONLY constitutes a smaller part of the sales and mostly says something about the interest in the pill. The pill is also sold through several large sales channels, including NovoCare online (Novo Nordisk's own online pharmacy), telehealth (Ro, GoodRx, LifeMD, Weight Watchers, Amazon Pharmacy etc.) and insurance (Medicaid/Medicare), but all those prescription numbers are invisible and only appear in the quarterly report. The total weekly prescription number is therefore larger than what is published by IQVIA, probably 1.5 - 4 times larger according to estimates from ChatGPT. Furthermore, it is important to include in one's revenue expectations that the price of Wegovy increases when the introductory period expires and when the dose is increased over time. Hope that Novo continues the good start to the year and that we have finally seen a turning point in the share price for shareholders :)·1 t sittenAgreed, remember the weather can have an impact (less last week, more current), and with the solid go-to-market strategy regarding the commercial part we have seen, I think the other channels will surprise tremendously. However, I think guidance will be affected by a cautious approach, so we probably won't get the fully positive aspect until the q1-26 figures are on the table, but I think it's set for 🚀 by then. Time will tell, but remember guidance is characterized by budget allocation that is probably signed off by November at the latest. P1 actuals are probably not closed on Wednesday and it's too early to update a DF. Anyhow, it will be exciting on Wednesday!
- ·3 t sittenConsidering buying now?
- ·5 t sittenSince the first super prescription numbers for the pill came three weeks ago, there has at the time of writing been 5 kr on the price.·4 t sitten · Muokattu56.000 prescriptions at 149 USD is approximately 56 million kroner. If we calculate with 26.000 prescriptions per week, that gives 1.3 billion DKK in annual revenue. In 2024, NOVO generated 290,4 billion DKK in revenue. 1,3 billion constitutes approximately ~0.5% of total revenue. 5 kr constitutes ~2% of the share price. Why do you think the price should be higher due to the pill sales figures at the current time?·2 t sittenYou are right if NN in the future only sells 26,000 prescriptions per week, i.e. 1.25 million prescriptions per year, then each prescription must cost 19,000 DKK per month to reach 290 billion in revenue per year. So it will be difficult, no matter how you look at it. However, I think the potential is incredibly large with 1 billion potential customers globally. What we have seen in the first few weeks merely shows that there is very great interest in the USA. Regarding the price, 149 USD is an introductory price for some for the first three months. Others have a completely different price. Furthermore, there will be significant sales from NN's own platforms, where NN controls most of the value chain and bypasses expensive sales channels, which will greatly benefit the bottom line.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 432 651
Myynti
Määrä
2 429 737
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 125 | - | - | ||
| 689 | - | - | ||
| 16 | - | - | ||
| 228 | - | - | ||
| 449 | - | - |
Ylin
377,65VWAP
Alin
366,45VaihtoMäärä
2 264,2 6 104 675
VWAP
Ylin
377,65Alin
366,45VaihtoMäärä
2 264,2 6 104 675
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 6 480 | 6 480 | 0 | 6 480 |
| DnB Bank ASA | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 5 940 447 | 5 940 447 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 143 331 | 143 331 | 0 | 143 331 |
| DCAR | 2 417 | 2 417 | 0 | 2 417 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 6 480 | 6 480 | 0 | 6 480 |
| DnB Bank ASA | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 5 940 447 | 5 940 447 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 143 331 | 143 331 | 0 | 143 331 |
| DCAR | 2 417 | 2 417 | 0 | 2 417 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
2025 Q3 -tulosraportti
85 päivää sitten54 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·57 min sittenI don't really care if the price rises or falls right now. I'm looking at at least a 5-year perspective : Novo Nordisk is extremely strong, not only here and now, but also in the long run. Several structural and strategic factors indicate that the share price has good conditions for a stable, gradual increase over the next five years. 1. Healthcare megatrends speak Novo's language The incidence of diabetes and obesity is rising globally, driven by demographics, urbanization, and lifestyle. Novo Nordisk is a world leader precisely in these diseases and is positioned where demand is growing fastest. 2. Strong pipeline and continuous innovation Novo has repeatedly shown the ability to improve existing treatments and develop new ones. This provides both longer product life cycles and the opportunity to expand indications, an important driver for long-term growth. 3. Scalable business with high earnings The company has a proven ability to translate growth into solid margins and strong cash flow. This allows for investments, acquisitions, share buybacks, and stable dividends, all supporting the share price. 4. Global reach and strong brand Novo Nordisk is not dependent on one market. Its global presence reduces risk and provides access to growth in both mature and new healthcare markets. 5. Long-term management and clear strategy The company is known for disciplined capital allocation and long-term thinking. This gives investors confidence, and confidence is often an underestimated factor behind stable price increases. Overall, Novo Nordisk is an example of a company where long-term societal trends, strong innovation, and a solid business model are moving in the same direction. This does not make the stock risk-free , but it makes it structurally interesting for many years to come.
- ·1 t sittenWill we close in the green today? 😁·31 min sittenThanks for your reply. I started here a few days ago so I didn't quite realize it kept running😏·24 min sittenRead along and separate the wheat from the chaff – then the rest is up to you 😉
- ·2 t sitten · MuokattuThanks to several for putting the sales figures of Wegovy pills into perspective. However, it is important to understand where the weekly prescription numbers come from, because it is only the tip of the iceberg. They are based on data from IQVIA, which are retail pharmacies in the USA, i.e. CVS, Walgreens, Rite Aid, Costco and Walmart, but this ONLY constitutes a smaller part of the sales and mostly says something about the interest in the pill. The pill is also sold through several large sales channels, including NovoCare online (Novo Nordisk's own online pharmacy), telehealth (Ro, GoodRx, LifeMD, Weight Watchers, Amazon Pharmacy etc.) and insurance (Medicaid/Medicare), but all those prescription numbers are invisible and only appear in the quarterly report. The total weekly prescription number is therefore larger than what is published by IQVIA, probably 1.5 - 4 times larger according to estimates from ChatGPT. Furthermore, it is important to include in one's revenue expectations that the price of Wegovy increases when the introductory period expires and when the dose is increased over time. Hope that Novo continues the good start to the year and that we have finally seen a turning point in the share price for shareholders :)·1 t sittenAgreed, remember the weather can have an impact (less last week, more current), and with the solid go-to-market strategy regarding the commercial part we have seen, I think the other channels will surprise tremendously. However, I think guidance will be affected by a cautious approach, so we probably won't get the fully positive aspect until the q1-26 figures are on the table, but I think it's set for 🚀 by then. Time will tell, but remember guidance is characterized by budget allocation that is probably signed off by November at the latest. P1 actuals are probably not closed on Wednesday and it's too early to update a DF. Anyhow, it will be exciting on Wednesday!
- ·3 t sittenConsidering buying now?
- ·5 t sittenSince the first super prescription numbers for the pill came three weeks ago, there has at the time of writing been 5 kr on the price.·4 t sitten · Muokattu56.000 prescriptions at 149 USD is approximately 56 million kroner. If we calculate with 26.000 prescriptions per week, that gives 1.3 billion DKK in annual revenue. In 2024, NOVO generated 290,4 billion DKK in revenue. 1,3 billion constitutes approximately ~0.5% of total revenue. 5 kr constitutes ~2% of the share price. Why do you think the price should be higher due to the pill sales figures at the current time?·2 t sittenYou are right if NN in the future only sells 26,000 prescriptions per week, i.e. 1.25 million prescriptions per year, then each prescription must cost 19,000 DKK per month to reach 290 billion in revenue per year. So it will be difficult, no matter how you look at it. However, I think the potential is incredibly large with 1 billion potential customers globally. What we have seen in the first few weeks merely shows that there is very great interest in the USA. Regarding the price, 149 USD is an introductory price for some for the first three months. Others have a completely different price. Furthermore, there will be significant sales from NN's own platforms, where NN controls most of the value chain and bypasses expensive sales channels, which will greatly benefit the bottom line.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 432 651
Myynti
Määrä
2 429 737
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 125 | - | - | ||
| 689 | - | - | ||
| 16 | - | - | ||
| 228 | - | - | ||
| 449 | - | - |
Ylin
377,65VWAP
Alin
366,45VaihtoMäärä
2 264,2 6 104 675
VWAP
Ylin
377,65Alin
366,45VaihtoMäärä
2 264,2 6 104 675
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 6 480 | 6 480 | 0 | 6 480 |
| DnB Bank ASA | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 5 940 447 | 5 940 447 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 143 331 | 143 331 | 0 | 143 331 |
| DCAR | 2 417 | 2 417 | 0 | 2 417 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 6 480 | 6 480 | 0 | 6 480 |
| DnB Bank ASA | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 5 940 447 | 5 940 447 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 143 331 | 143 331 | 0 | 143 331 |
| DCAR | 2 417 | 2 417 | 0 | 2 417 |